Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06207929 · ClinicalTrials.gov registry record

Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections

A clinical trial of COVID-19 and Influenza, Human, sponsored by Evidation Health.

Completed
Registry status
18,157
Enrollment target
1
Study location

NCT06207929: Completed study of COVID-19 and Influenza, Human, sponsored by Evidation Health.

NCT06207929 is a study of COVID-19 and Influenza, Human that has completed, run by Evidation Health. The registered enrollment target is 18,157 participants, below the 38,404-participant average among 298 other COVID-19 trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06207929, a study of COVID-19 and Influenza, Human, has completed, sponsored by Evidation Health.

COMPLETED
Registry status
18,157 participants
Enrollment target
1
Study location

Study Summary

The goal of this decentralized, observational study is to enroll and observe adults in the contingent United States during the 2023-2024 flu season. The main study objectives are to create a dataset of paired wearable data, self-reported symptoms, and respiratory viral infection (RVI) from PCR testing during the 2023-2024 flu season and to develop algorithm that is able to accurately classify asymptomatic and symptomatic RVI and understand the algorithm's performance metrics.

Primary Outcome

This study will gather wearable device data, including heart rate, sleep, activity, and other data types from commercially available wearable activity trackers and smartwatches (e.g. Apple Watch, Fitbit, Garmin devices), as well as self-reported data related to the experience of symptoms associated with respiratory viral infections, and pair this data with the results from PCR tests of serial at-home nasal swabs for SARS-CoV-2, Influenza A, Influenza B, and respiratory syncytial virus (RSV). Thi

Study Locations (1)

California

  • Evidation Health - San Mateo

Trial Details

FieldValue
Enrollment Target 18,157 participants
Start Date 2024-01-21
Est. Completion 2024-08-07
Evidation Health

12 total trials

What the finished NCT06207929 record still lists

NCT06207929 is an observational study that tracks outcomes without assigning an intervention. Its 18,157 participants enrollment target places it among the larger protocols in the corpus, below the 38,404-participant average among 298 other COVID-19 trials with a reported enrollment target (53% lower).

The record links to 5 conditions, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.

NCT06207929 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06207929 about?

NCT06207929 is a clinical study titled "Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections". The goal of this decentralized, observational study is to enroll and observe adults in the contingent United States during the 2023-2024 flu season. The main study objectives are to create a dataset of paired wearable data, self-reported symptoms, and respiratory viral infection (RVI) from PCR testi...

What is the current status of trial NCT06207929?

This trial is currently completed. The enrollment target is 18,157 participants. The study started on 2024-01-21. Estimated completion is 2024-08-07.

What conditions does trial NCT06207929 study?

This clinical trial studies the following conditions: COVID-19, Influenza, Human, Respiratory Syncytial Virus (RSV), Influenza a, Influenza B.

Who is sponsoring clinical trial NCT06207929?

This trial is sponsored by Evidation Health, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06207929 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06207929's enrollment target sits among peer trials

18,157 19th of 298 higher than 280 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04110522 · 18,000 participants · NA

    Psoriatic Arthritis D2P Screening

  • NCT05513833 · 18,000 participants · NA

    School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Kentucky

  • NCT06802224 · 18,000 participants · Phase 4

    The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery

  • NCT04372875 · 18,500 participants · NA

    Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06207929, the US trial registry maintained by the National Library of Medicine. NCT06207929 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.